Cargando…

Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases...

Descripción completa

Detalles Bibliográficos
Autores principales: Cennamo, Gilda, Montorio, Daniela, D’ Andrea, Luca, Farella, Antonio, Matano, Elide, Giuliano, Mario, Liuzzi, Raffaele, Breve, Maria Angelica, De Placido, Sabino, Cennamo, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763327/
https://www.ncbi.nlm.nih.gov/pubmed/35047387
http://dx.doi.org/10.3389/fonc.2021.754108
_version_ 1784633911544905728
author Cennamo, Gilda
Montorio, Daniela
D’ Andrea, Luca
Farella, Antonio
Matano, Elide
Giuliano, Mario
Liuzzi, Raffaele
Breve, Maria Angelica
De Placido, Sabino
Cennamo, Giovanni
author_facet Cennamo, Gilda
Montorio, Daniela
D’ Andrea, Luca
Farella, Antonio
Matano, Elide
Giuliano, Mario
Liuzzi, Raffaele
Breve, Maria Angelica
De Placido, Sabino
Cennamo, Giovanni
author_sort Cennamo, Gilda
collection PubMed
description Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases, and patients’ survival rate during 4 years’ follow-up. A total of 355 eyes from 355 patients have been treated with Ru-106 plaque brachytherapy for uveal melanoma between February 2011 and March 2020. Five patients were lost to follow-up, and then 350 eyes of 350 patients (mean age 58 ± 11 years) were enrolled in this retrospective study. All patients underwent a complete ophthalmic examination including echography and spectral domain–optical coherence tomography. The mean follow-up was 4 years (3 months to 9 years). After treatment, the mean tumor thickness was reduced to 1.75 ± 0.21 mm. Radiation complications were found in 63% of patients: 38% showed radiation maculopathy, 11% had optic neuropathy, and 14% developed cataracts. Cancer-free survival was 99%, 97%, and 85%, respectively, at 5, 7, and 9 years. Ru-106 plaque brachytherapy represents a reliable treatment of uveal melanoma. This technique is valid and safe with a low rate of ocular complications during a long-term follow-up.
format Online
Article
Text
id pubmed-8763327
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87633272022-01-18 Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy Cennamo, Gilda Montorio, Daniela D’ Andrea, Luca Farella, Antonio Matano, Elide Giuliano, Mario Liuzzi, Raffaele Breve, Maria Angelica De Placido, Sabino Cennamo, Giovanni Front Oncol Oncology Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases, and patients’ survival rate during 4 years’ follow-up. A total of 355 eyes from 355 patients have been treated with Ru-106 plaque brachytherapy for uveal melanoma between February 2011 and March 2020. Five patients were lost to follow-up, and then 350 eyes of 350 patients (mean age 58 ± 11 years) were enrolled in this retrospective study. All patients underwent a complete ophthalmic examination including echography and spectral domain–optical coherence tomography. The mean follow-up was 4 years (3 months to 9 years). After treatment, the mean tumor thickness was reduced to 1.75 ± 0.21 mm. Radiation complications were found in 63% of patients: 38% showed radiation maculopathy, 11% had optic neuropathy, and 14% developed cataracts. Cancer-free survival was 99%, 97%, and 85%, respectively, at 5, 7, and 9 years. Ru-106 plaque brachytherapy represents a reliable treatment of uveal melanoma. This technique is valid and safe with a low rate of ocular complications during a long-term follow-up. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8763327/ /pubmed/35047387 http://dx.doi.org/10.3389/fonc.2021.754108 Text en Copyright © 2022 Cennamo, Montorio, D’ Andrea, Farella, Matano, Giuliano, Liuzzi, Breve, De Placido and Cennamo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cennamo, Gilda
Montorio, Daniela
D’ Andrea, Luca
Farella, Antonio
Matano, Elide
Giuliano, Mario
Liuzzi, Raffaele
Breve, Maria Angelica
De Placido, Sabino
Cennamo, Giovanni
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
title Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
title_full Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
title_fullStr Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
title_full_unstemmed Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
title_short Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
title_sort long-term outcomes in uveal melanoma after ruthenium-106 brachytherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763327/
https://www.ncbi.nlm.nih.gov/pubmed/35047387
http://dx.doi.org/10.3389/fonc.2021.754108
work_keys_str_mv AT cennamogilda longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT montoriodaniela longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT dandrealuca longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT farellaantonio longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT matanoelide longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT giulianomario longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT liuzziraffaele longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT brevemariaangelica longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT deplacidosabino longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy
AT cennamogiovanni longtermoutcomesinuvealmelanomaafterruthenium106brachytherapy